Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
The US Food and Drug Administration (FDA) has rejected PTC Therapeutics’ new drug application (NDA) for vatiquinone in Friedreich's Ataxia. This follows the biotech’s decision to submit the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback